COVID-19 Pediatric Rheumatology Survey

COVID-19 pandemic has threatened millions of lives worldwide. We would like to learn about the way it has changed our pediatric rheumatology practice. Please take five minutes to complete the below survey.
1.What is your age?(Required.)
2.What is your gender?(Required.)
3.Which setting do you practice in?(Required.)
4.Which country do you practice in?(Required.)
5.Years in pediatric rheumatology practice:(Required.)
6.Do you prescribe any of the following drugs less often in your current practice because of the COVID-19 pandemic?(Required.)
7.Which biologic drugs do you hesitate most in initiating during the COVID-19 pandemic?(Required.)
8.Which non-biologic/conventional synthetic disease modifying anti-rheumatic drugs (DMARDs) do you hesitate most in initiating during the COVID-19 pandemic?(Required.)
9.If your patient contracted COVID-19, how was the underlying rheumatic disease affected?(Required.)
10.Do you modify anti-rheumatic treatment if your patient has COVID-19?(Required.)
11.How do you modify biologic treatment if your patient has COVID-19?(Required.)
12.Select the adjustments made in your clinical practice after 2.5 years of COVID-19 pandemic:(Required.)
13.Which percentage of your clinical practice is currently based on telemedicine tools?(Required.)
14.There are still delays in the diagnosis or treatment of pediatric rheumatic diseases due to the COVID-19 pandemic.(Required.)
15.Our clinical practice is returning to routine, as prior to the pandemic.(Required.)
16.The vaccination policies have decreased the impact of COVID-19 on pediatric rheumatology practice.(Required.)
17.Vaccines against COVID-19 in childhood will reduce the prevalence of multisystem inflammatory syndrome in children (MIS-C)/pediatric inflammatory multisystem syndrome (PIMS).(Required.)
18.Do you contribute to the management of MIS-C/PIMS patients?(Required.)